European Archives - Page 321 of 1156 - European Medical Journal

Novel Treatments for Systemic Sclerosis: EULAR 2024 Findings

EULAR has updated its recommendations for systemic sclerosis, incorporating four new therapies presented at its congress in 2024.

Biomedical Alliance in Europe: A Roundtable Discussion

Tune in to the latest EMJ Webinar, featuring three of the Biomedical Alliance in Europe’s most valued members, who join host Jonathan…

New MS blood test to launch in Europe

Siemens Healthineers has received CE Mark approval for its test for the management of relapsing multiple sclerosis, allowing it to be launched in Europe.

AML Expert Exchange: Interactive Webinar

Watch this expert-led webinar on acute myeloid leukaemia (AML) maintenance therapy discussing clinical guidelines and evidence…

EuroPCR 2024 Interview: Julien Dreyfus

I began my residency in cardiology at Bichat Hospital in Paris, France. At that time, it was one of the leading institutions for valvular…

Fetal Origins of Paediatric Acute Myeloid Leukaemia

Researchers have uncovered crucial insights into the development of paediatric acute myeloid leukaemia, revealing that some cases may originate in the womb

Telehealth Equally Effective as In-Person Palliative Care for Advanced Lung Cancer Patients

A recent trial has shown that telehealth delivery of early palliative care is as effective as in-person visits for patients with advanced non-small cell lung cancer

Challenge to Reduce Bleeding Risk from Low-Dose Direct Oral Anticoagulants

A new study finds that low-dose direct oral anticoagulants are linked to an increased risk of early bleeding episodes in patients with atrial fibrillation, compared to standard-dose

Ultra-Low-Dose Radiotherapy Effective for Gastric Lymphoma Treatment

Researchers have aimed to investigate how to ensure the safety of ultra-low-dose radiotherapy in a patient cohort diagnosed with gastric lymphoma.

Osimertinib Extends Progression-Free Survival in EGFR-Mutant Lung Cancer

A Phase 3 trial reveals that osimertinib significantly extends progression-free survival in patients with unresectable stage III EGFR-mutant non-small cell lung cancer after chemoradiotherapy